SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Exploring the Causal Links Between 338 Cerebrospinal Fluid Metabolites and Parkinson's Disease.

Brain Behav · 2025-09-01

DOI: 10.1002/brb3.70815PMID: 40891182

Open accessresearch-article; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundParkinson's disease (PD) is a progressive neurodegenerative condition characterized by motor impairments and intricate pathophysiological mechanisms. Although cerebrospinal fluid (CSF) metabolites are viewed as potential biomarkers, the primarily observational design of the majority of existing studies limits the ability to draw causal conclusions.ObjectiveThe purpose of this research was to explore the causal link between CSF metabolites and PD by employing two-sample Mendelian randomization (TSMR).MethodsData on CSF metabolites were acquired from the two longitudinal cohort studies. Information regarding PD was gathered from the International Parkinson's Disease Genomics Consortium. Instrumental variables (IVs) for 338 CSF metabolites were identified based on notable SNPs. Causal impacts were assessed using Mendelian randomization techniques including inverse variance weighted (IVW) analysis and MR-Egger regression. The analyses included sensitivity assessments to evaluate issues related to heterogeneity and pleiotropy.ResultsSignificant causal associations were found between several CSF metabolites and PD. Higher levels of glycerophosphoinositol, sphingomyelin, and oxalate were linked to increased PD risk, while elevated caffeine levels appeared protective. After FDR correction, glycerophosphoinositol, oxalate, and caffeine remained significant. Sensitivity analyses confirmed robustness with no heterogeneity or pleiotropy.ConclusionThis analysis of MR reveals multiple CSF metabolites that have causal links to PD. Increased levels of glycerophosphoinositol and oxalate are associated with higher risk, whereas caffeine provide protective benefits. These metabolites may act as potential biomarkers and treatment targets for PD.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.